Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.



Lay summary

The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol, in patients with chronic schizophrenia.





We have no "publications" for this trial. Help us by contributing data.


Methodological rigour

The methodological rigour of this trial was scored in a systematic review, where it was scored as being at "unclear" for "sequence generation", "unclear" for "allocation concealment", "low risk" of bias for "blinding (performance)", "unclear" for "blinding (detection)", "high risk" of bias for "attrition", "low risk" of bias for "reporting", and "unclear" for "other biases". Read more about what this means.